Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

633
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
633
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

591
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
591
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

565
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
565
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

837
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
837
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

954
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
954

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunctive GLP1 Receptor Agonists in Patients with Inflammatory Bowel Diseases and Obesity and/or Diabetes: A Target Trial Emulation.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

EGFR INHIBITION PROMOTES ENTEROENDOCRINE CELL DIFFERENTIATION CONTRIBUTING TO TREATMENT-ASSOCIATED DIARRHEA.

bioRxiv : the preprint server for biology·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

ST8Sia6-dependent glycosylation restrains gut inflammation and pathogenic T<sub>h</sub>1 and T<sub>h</sub>17 programs.

Cell reports·2026
Same author

Intestinal Stem Cells From Patients With Inflammatory Bowel Disease Retain an Epigenetic Memory of Inflammation.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Next-Generation regulatory T cell therapies: Translational considerations for inflammatory bowel disease.

Human immunology·2026
Same journal

Living Donor Intestinal and Liver Transplantation.

Gastroenterology clinics of North America·2026
Same journal

Living Abdominal Organ Donation: A Plan B That Saves Lives.

Gastroenterology clinics of North America·2026
Same journal

Long-Term Outcomes of Living Liver Donors.

Gastroenterology clinics of North America·2026
Same journal

Perioperative Management of Living Liver Donor Patients.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Transplantation for Colorectal Cancer Liver Metastasis.

Gastroenterology clinics of North America·2026
Same journal

Living Donor Liver Graft in Adult Populations: Donor Selection and Workup.

Gastroenterology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.1K

Targeting Specific Immunologic Pathways in Crohn's Disease.

Guilherme Piovezani Ramos1, William A Faubion2, Konstantinos A Papadakis2

  • 1Department of Internal Medicine, College of Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

Gastroenterology Clinics of North America
|August 26, 2017
PubMed
Summary
This summary is machine-generated.

Developing new therapies for intestinal inflammation involves understanding immunologic pathways. Targeting integrins and cytokines, like the interleukin-12/23 pathway, aims to control leukocyte migration and reduce inflammation in Crohn

Keywords:
Crohn's diseaseImmunologyInflammatory bowel diseasesTarget therapy

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.7K

Related Experiment Videos

Last Updated: Feb 24, 2026

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

2.1K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

6.0K
Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells
06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

9.7K

Area of Science:

  • Immunology
  • Gastroenterology
  • Pharmacology

Background:

  • Intestinal inflammation requires novel therapeutic strategies for improved patient outcomes.
  • Current treatments focus on controlling leukocyte migration and inflammatory cytokines.
  • Understanding underlying immunologic pathways is key to developing targeted therapies.

Purpose of the Study:

  • To explore immunologic pathways in intestinal inflammation.
  • To identify new therapeutic targets for Crohn's disease (CD).
  • To enhance anti-inflammatory cytokine pathways and modulate cellular responses.

Main Methods:

  • Investigating integrin receptors on intestinal vascular endothelium.
  • Analyzing the interleukin (IL)-12/IL-23 pathway as a therapeutic target.
  • Exploring modulation of cellular responses and intranuclear signals.

Main Results:

  • Targeting integrins can prevent leukocyte migration to inflammatory sites.
  • The IL-12/IL-23 pathway is a significant target for active CD.
  • Enhancing anti-inflammatory cytokines shows promise for CD treatment.

Conclusions:

  • New therapies for intestinal inflammation can be developed by targeting integrins and cytokines.
  • Modulating the IL-12/IL-23 pathway offers a promising approach for Crohn's disease.
  • Future strategies may involve enhancing anti-inflammatory pathways and cellular signaling.